Background: Kaposi sarcoma herpesvirus (KSHV) causes malignancies in patients with AIDS or immunosuppression. Results: KSHV represses tumor suppressor gene PDLIM2, whose reconstitution suppresses tumorigenesis of KSHVassociated cancer cells. Conclusion: KSHV suppresses PDLIM2 for tumorigenesis. Significance: These studies not only reveal an important mechanism underlying KSHV pathogenesis but also provide immediate therapeutic strategies for KSHV-mediated cancers.
Kaposi sarcoma herpesvirus (KSHV) is the most common cause of malignancies among AIDS patients. However, how KSHV induces tumorigenesis remains largely unknown. Here, we demonstrate that one important mechanism underlying the tumorigenesis of KSHV is through transcriptional repression of the tumor suppressor gene PDZ-LIM domain-containing protein 2 (PDLIM2). PDLIM2 expression is repressed in KSHVtransformed human umbilical vascular endothelial cells as well as in KSHV-associated cancer cell lines and primary tumors.
Importantly, PDLIM2 repression is essential for KSHV-induced persistent activation of nuclear factor B (NF-B) and signal transducer and activator of transcription 3 (STAT3) and subsequent tumorigenesis and tumor maintenance. Our mechanistic studies indicate that PDLIM2 repression by KSHV involves DNA methylation. Notably, the epigenetic repression of PDLIM2 can be reversed by 5-aza-2-deoxycytidine and vitamin D to suppress KSHV-associated cancer cell growth. These stud-ies not only improve our understanding of KSHV pathogenesis but also provide immediate therapeutic strategies for KSHVmediated cancers, particularly those associated with AIDS.
KSHV, 3 also known as human herpesvirus 8 (HHV8), was identified in 1990s as the etiological agent of three malignancies mainly associated with AIDS and immunosuppression: Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (1) (2) (3) . Since then, the molecular biology of this oncovirus has been extensively studied (4 -6) . However, the molecular mechanisms by which KSHV induces tumorigenesis still remain obscure. Those characterized to date suggest that although its lytic infection contributes in a paracrine manner, the latent infection of KSHV is the direct driving force in tumor formation and maintenance with the expression of a limited set of viral genes capable of hijacking cellular signaling pathways important for host cell proliferation and survival.
Among those host cell signaling pathways hijacked by KSHV, the NF-B and STAT3 pathways, which have been shown to play a causative role in the formation and therapeutic resistance of several tumor types, are particularly important for the pathogenesis of KSHV. In fact, constitutive activation of NF-B and STAT3 has been found to be essential for all key steps of KSHV tumorigenesis, from viral latency to cell transformation to tumor formation and maintenance .
The molecular mechanisms of how KSHV activates NF-B and STAT3 have been well defined . However, it remains unknown how the activated NF-B and STAT3 fail to be turned off in KSHV tumorigenesis. Under normal conditions, activation of NF-B and STAT3 is usually transient. One essential mechanism for terminating activation of both NF-B RelA and STAT3 involves polyubiquitination and proteasomal degradation of their nuclear activated forms mediated by PDLIM2 (33) (34) (35) . Accordingly, the expression of PDLIM2 has been found to be epigenetically repressed in several tumors associated with persistent activation of RelA (36 -39) . Thus, it is of interest and importance to examine whether and how PDLIM2 is repressed by KSHV and whether PDLIM2 repression by KSHV is involved in the persistent RelA and STAT3 activation and subsequent tumor formation and maintenance. These studies will not only increase our understanding of KSHV pathogenesis but may also form novel therapeutic strategies for KSHV-associated tumors, particularly those related to AIDS. tion mutant, NF-B-or STAT3-driven firefly luciferase reporters, thymidine kinase-driven Renilla luciferase reporter, and antibodies specifically recognizing Myc, PDLIM2, 20 S proteasome, promyelocytic leukemia protein, and SC-35 have been described before (36, 40 -42) . Lentiviral vector pLL3.7 expressing shRNAs specifically against human PDLIM2, RelA, or STAT3 were generated as described previously (41) . Sp1, Hsp90, RelA, and STAT3 antibodies as well as the secondary antibodies were from Santa Cruz Biotechnology (Dallas, TX). Phorbol myristate acetate, sodium butyrate, 5-aza-dC, and 1␣,25-dihydroxyvitamin D3 (1,25(OH) 2 D 3 ) were purchased from Sigma-Aldrich.
Cells and Viruses-HUVECs were cultured in VascuLife VEGF cell culture medium (Lifeline Cell Technology). Human PEL cell lines BCBL-1, BC-1, and BCP-1 were maintained in RPMI 1640 medium supplemented with 10% FBS. BCBL-1 cells were treated with phorbol myristate acetate (20 ng/ml) and sodium butyrate (1 mM) for 3 days to produce infectious KSHV viruses for in vitro transformation of HUVECs.
Quantitative Polymerase Chain Reaction (qPCR) Analysis-Cells were subjected to RNA extraction, RNA reverse transcription, and real-time PCR as described (37) (38) (39) . The expression levels of PDLIM2 were normalized to that of GAPDH. Primer pairs for GAPDH, PDLIM2, DNMT1, DNMT3a, and DNMT3b were published previously (37) . Other primers are: Bcl-x L , forward 5Ј-GAATGACCACCTAGAGCCTTGG-3Ј, reverse 5Ј-TGTTCCC-ATAGAGTTCCACAAAAG-3Ј; survivin, forward 5Ј-TGACGA-CCCCATAGAGGAACA-3Ј, reverse 5Ј-CGCACTTTCTCCGC-AGTTTC-3Ј; and cyclin D1, forward 5Ј-CCGTCCATGCGGAA-GATC-3Ј, reverse 5Ј-ATGGCCAGCGGGAAGAC-3Ј.
Retroviral Transduction and Generation of Stable Transfectant-PEL cell lines stably expressing PDLIM2, PDLIM2 mutants, shRNAs against RelA, STAT3, or PDLIM2 were generated as described before (43) .
Soft Agar Assays-Cells suspended in culture medium containing 0.6% SeaPlaque low melting agarose were plated on the top of 1% agarose in culture medium as described before (43) . Colonies in soft agar were counted 12 days after plating.
Establishment of Tumors and Ascites in Mice-Four-to sixweek-old SCID mice were injected intraperitoneally or subcutaneously with 5 ϫ 10 6 PEL cells for ascites and/or tumor formation as described previously (44) . The protocols were approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.
Histopathology and Immunohistochemistry (IHC) Assays-Formalin-fixed human normal and KS tissues were embedded in paraffin, sectioned, and then subjected to IHC staining as described previously (45) .
Immunoblotting (IB) Analysis-Whole cell lysates and nuclear extracts were prepared and used for SDS-PAGE and IB as described previously (46, 47) . The purity of cell nuclear fractions was confirmed by the detection of Sp1 (nuclear marker) but no Hsp90 (cytosolic marker) in IB.
Confocal Microscopic Analysis-The indicated PEL stable cell lines were subjected to immunofluorescence staining as described before (36) . The subcellular localization of stained proteins was visualized by an Olympus FluoView 1000 confocal microscope (Melville, NY).
Luciferase Gene Reporter Assays-The indicated cells were transfected with NF-Bor STAT3-driven firefly luciferase reporters together with thymidine kinase-driven Renilla luciferase reporter. At 40 h after transfection, Dual-Luciferase activities were measured as described previously (41) .
Bisulfite Genomic DNA Sequencing-As described before (38, 39) , genomic DNAs from 5-aza-dC-treated or mocktreated cells were isolated, and aliquots were then treated with sodium bisulfite followed by PCR to amplify the PDLIM2 promoter and DNA sequencing to determine the methylation status of the CpG dinucleotides within the pdlim2 promoter.
Statistical Analysis-Data were reported as mean Ϯ S.D. The Student's t test (two-tailed) was used to assess significance of differences between two groups. p values Ͻ 0.05 and 0.01 were considered statistically significant and highly statistically significant, and indicated by * and **, respectively.
RESULTS

PDLIM2 Expression Is Repressed in KSHV-transformed Cells and Primary Tumor Tissues-To investigate whether PDLIM2
is involved in the pathogenesis of KSHV, we initially examined the expression levels of PDLIM2 in human PEL cell lines BCBL-1, BC-1, and BCP-1. In comparison with the virus-free lymphoblastoid B-cell line BJAB, all three PEL cell lines had much lower expression of PDLIM2 RNA (Fig. 1A) . Similarly, the RNA expression level of PDLIM2 was significantly suppressed in KSHV-transformed HUVECs, in comparison with normal HUVECs (Fig. 1B) . These data suggest that PDLIM2 expression is repressed by KSHV starting from the very early stage of tumorigenesis.
To validate the clinic significance of this finding, we examined the expression of PDLIM2 in human primary tissues of KS associated with KSHV. In line with its ubiquitous expression in murine tissues/cells (48) , PDLIM2 was readily detected in various cell types of KSHV-negative normal tissues (Fig. 1C , left panel). However, little PDLIM2 was detected in primary KS cells (Fig. 1C, right panel) . These data indicated that PDLIM2 repression is relevant to KSHV-associated tumors both pathogenically and clinically.
PDLIM2 Reconstitution Blocks HUVEC Transformation by KSHV and Suppresses the Tumorigenicity of KSHV-associated PEL Cells Both in Vitro and in Vivo-
To determine the significance of PDLIM2 down-regulation in the pathogenesis of KSHV, we first examined whether PDLIM2 reconstitution prevents KSHV-mediated transformation of HUVECs. To do so, we generated HUVECs stably expressing exogenous PDLIM2 or an empty vector ( Fig. 2A, upper panels) . Expression of exogenous PDLIM2 had no obvious effect on the morphology of HUVECs ( Fig. 2A, middle panel) . In agreement with previous studies (49) , infection of KSHV resulted in dramatic induction of spindle-shaped morphology, a hallmark of KS, in HUVECs expressing empty vector ( Fig. 2A, bottom panel, left) . However, no significant morphology change was observed in HUVECs expressing PDLIM2 after the same infection ( Fig. 2A, bottom  panel, right) . These data suggest that PDLIM2 suppresses KSHV-mediated cell transformation.
Next, we examined whether PDLIM2 reconstitution can reverse the malignant phenotype of PEL cells. When compared with their vector-expressing control cells, BCBL-1 and BC-1 cells stably expressing PDLIM2 showed a slight, but statistically significant, decrease in growth rate even when 10% FBS was provided in their culture medium (Fig. 2B) . The difference was much more dramatic when the supplemented FBS was decreased to 5%. More importantly, the PDLIM2 stable cell lines formed far fewer colonies in soft agar (Fig. 2C) . These data clearly suggest that PDLIM2 re-expression suppresses the tumorigenicity of KSHV-associated PEL cells in vitro.
To confirm the in vitro studies in vivo, we subcutaneously inoculated the vector control and PDLIM2-expressing PEL cell lines into the opposite flanks of SCID mice. As shown in Fig. 2D , both vector control and PDLIM2-expressing PEL cell lines developed tumors at the inoculation sites in mice. However, the tumors formed by the PDLIM2-expressing cancer cell lines were significantly smaller than those formed by the vector control cell lines. To validate these studies in a different in vivo model of human PEL, the PEL stable cell lines were intraperitoneally injected into SCID mice. In agreement with previous studies (44) , SCID mice injected with the vector control PEL cell lines developed malignant ascites and effusion lymphomas in various organs ( Fig. 2E) . However, the severity of both ascites and lymphomas in mice injected with the PDLIM2 stable PEL cell lines was significantly lower. These data together indicate that PDLIM2 down-regulation is one important mechanism underlying both the tumorigenesis and the tumor phenotype maintenance of KSHV-associated tumors.
PDLIM2 Reconstitution Inhibits Oncogenic NF-B RelA and STAT3 Activation to Suppress KSHV Tumorigenesis-To define the molecular mechanism by which PDLIM2 down-regulation contributes to the pathogenesis of KSHV, we focused on RelA and STAT3, two downstream targets of PDLIM2. As expected, a high nuclear expression of RelA and STAT3 was detected in the BCBL-1-vector and BC-1-vector cells (Fig. 3, A and B) . However, the nuclear expression of RelA and STAT3 was inhibited in the BCBL-1-PDLIM2 and BC-1-PDLIM2 cells. The decrease of nuclear RelA and STAT3 was due to proteasomal degradation because treatment of the proteasome inhibitor MG132 led to increase of RelA and STAT3 at the nuclear matrix but not the promyelocytic leukemia or SC-35 bodies of those PDLIM2 stable cell lines (Fig. 3A) . Consistently, the transcription activities and downstream target genes of NF-B and STAT3, such as Bcl-x L , survivin, and cyclin D1, were also suppressed in those PDLIM2 stable cell lines (Fig. 3, C and D) . It is noteworthy that Bcl-x L , survivin, and cyclin D1 are known drivers of cell survival and proliferation.
To validate whether PDLIM2 suppresses KSHV tumorigenesis via termination of RelA and STAT3 activation, we utilized the PDLIM2 PDZ or LIM domain deletion mutants. In line with previous studies (33, 34, 38 -40) , the two mutants failed to prevent the nuclear expression of RelA and STAT3 in PEL cells (Fig. 3E) . Importantly, the two mutants also failed to suppress the growth and colony formation of PEL cells (Fig. 3, F and G) . In further support of this, knockdown of RelA or STAT3 resulted in significant growth inhibition of PEL cells (Fig. 3H) . Altogether, our studies suggest that KSHV somehow represses PDLIM2 expression, leading to persistent RelA and STAT3 activation and subsequent tumorigenesis and tumor phenotype maintenance.
PDLIM2 Repression Involves Its Promoter Methylation and Can Be Reversed by 5-aza-dC and Vitamin D to Inhibit Growth of KSHV-associated Tumor Cells-Given the role of PDLIM2 in KSHV pathogenesis and its potential application in the therapy of KSHV-associated tumors, it is of interest and importance to determine the molecular mechanism by which KSHV represses PDLIM2 expression. Our previous studies showed that PDLIM2 is epigenetically repressed in several cancer types (37) (38) (39) . Thus, we examined the methylation status of the pdlim2 promoter in PEL cells. We found that the pdlim2 promoter was indeed hyper-methylated in PEL cells, which could be reversed by the demethylation drug 5-aza-dC (Fig. 4A) . Moreover, the treatment of 5-aza-dC resulted in significant recovery of PDLIM2 expression in the PEL cells (Fig. 4B) . Interestingly, 5-aza-dC had a dose-dependent effect on PDLIM2 recovery at a concentration lower than 0.5 M. These data are consistent with the fact that 5-aza-dC induces expression of methylated genes at low doses and mainly exerts its cytotoxicity through inducing DNA damage at high doses. To determine how KSHV induces PDLIM2 promoter hyper-methylation for its repression, we examined the expression of all three DNA methyltransferases in PEL cells. We found that DNMT3a, but not DNMT1 or DNMT3b, was dramatically induced in BCBL-1 and BC-1 cells when compared with the virus-free BJAB cells (Fig. 4C) . These data suggest that KSHV represses PDLIM2 expression through inducing DNMT3a expression and pdlim2 promoter methylation. A recent study showed that vitamin D can induce PDLIM2 re-expression in human breast cancer cells through both DNA methylation-dependent and DNA methylation-independent mechanisms (50) . As expected, 1,25(OH) 2 D 3 , the biologically active form of vitamin D3, induced PDLIM2 re-expression in PEL cells (Fig. 4D) . Interestingly, 5-aza-dC and 1,25(OH) 2 D 3 could synergize in inducing PDLIM2 re-expression in PEL cells ( Fig. 4E ). Of note, re-induction of PDLIM2 by 5-aza-dC and 1,25(OH) 2 D 3 was associated with decreased transcriptional activity of NF-B and STAT3, as well as growth inhibition of PEL cells (Fig. 4, F and G) .
To determine whether PDLIM2 re-induction is involved in the antitumor activity of 5-aza-dC and 1,25(OH) 2 D 3 , we generated PEL cells stably expressing PDLIM2 shRNA, in which PDLIM2 re-induction by 5-aza-dC and 1,25(OH) 2 D 3 could be sufficiently blocked. Remarkably, the growth inhibition of PEL cells by 5-aza-dC and 1,25(OH) 2 D 3 was significantly inhibited by PDLIM2 knockdown (Fig. 4H) . These data not only provide the mechanistic insights into the KSHV-mediated repression of PDLIM2, but also suggest an immediate strategy to target PDLIM2 for the prevention and treatment of KSHV-associated tumors.
DISCUSSION
Twenty years ago, KSHV was demonstrated as the causative agent of three major AIDS-associated tumors. However, little progress has been made in targeting the virus for the treatment of these incurable tumors (51) . Recent studies suggest that persistent activation of NF-B and STAT3 plays critical roles in both KSHV-associated tumors and HIV-associated AIDS, therefore providing ideal therapeutic targets. However, clinical trials show that it is impractical to block NF-B activation for cancer therapy using classical NF-B inhibitors because of the physiological importance of NF-B in humans (52) . It also seems unfeasible to block virus-specific activation of NF-B for cancer therapy because NF-B activation by KSHV involves multiple mechanisms and multiple viral genes (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . A similar situation also applies to STAT3 (16, (27) (28) (29) (30) (31) (32) 45) . To meet these challenges, we have been focusing our studies on the termination mechanisms of NF-B and STAT3 activation in KSHV-associated tumors because the fundamental difference between physiological and pathogenic activation of NF-B and STAT3 is that the former is rapidly turned off and therefore transient, whereas the latter cannot be turned off and is therefore persistent.
Our studies presented in this study indicate that epigenetic repression of PDLIM2 is one important mechanism underlying the persistent activation of NF-B and STAT3 in KSHV tumorigenesis. Given the specific role of PDLIM2 in repressing pathogenic, but not physiologic, activation of NF-B and STAT3, PDLIM2-based therapies will alleviate NF-B-and STAT3mediated tumorigenesis and chemoradioresistance while keeping the physiological functions of NF-B and STAT3 largely intact in patients. Indeed, the expression of PDLIM2 can be restored by 5-aza-dC and vitamin D to suppress oncogenic NF-B and STAT3 activation and tumorigenicity of PEL cells. Of note, 5-aza-dC and vitamin D have already been used in humans and show very low toxicity. Thus, our studies not only provide mechanistic insights into the regulation and actions of the newly defined tumor suppressor PDLIM2, the oncogenic activation of NF-B and STAT3, the pathogenesis of KSHV- associated tumors, and the antitumor activity of 5-aza-dC and vitamin D, but also suggest the clinical feasibility of PDLIM2based therapies for KSHV-associated tumors and other tumors mediated by deregulated PDLIM2/NF-B/STAT3.
